Rejuveron Life Sciences

Rejuveron does not publicly identify any principals, investment committee members, or senior leadership. All public-facing materials operate through the Centenara Labs brand, which names only a contact address and phone number. No LinkedIn profile or third-party reporting fills the gap.

The firm describes building its pipeline by founding new companies around promising discoveries in aging research, rather than solely evaluating external in-licensing opportunities. Its scientific leadership translates hallmarks-of-aging biology into targeted therapeutic concepts, which are then funded into early-stage companies.

Rejuveron is not publicly described as a family office. It operates through Centenara Labs AG, a Swiss operating entity that functions as both a drug developer and a portfolio aggregator for early-stage therapeutics companies. No fund structure, limited partner base, or co-investor club is disclosed.

Endogena Therapeutics’ program for retinitis pigmentosa is the most advanced, having completed a Phase 1b/2a clinical study that demonstrated safety and early signs of efficacy. It received FDA Fast Track and Orphan Drug Designations. A second Endogena program for dry age-related macular degeneration received IND clearance in October 2023.

Rejuveron has not disclosed the source of its capital. There are no named individuals, wealth-origin disclosures, or regulatory filings that link the firm to a specific family fortune or institutional backer. Its Swiss corporate presence through Centenara Labs AG is the only visible structure.